346 related articles for article (PubMed ID: 28097317)
1. Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial.
Royce TJ; Chen MH; Wu J; Loffredo M; Renshaw AA; Kantoff PW; D'Amico AV
JAMA Oncol; 2017 May; 3(5):652-658. PubMed ID: 28097317
[TBL] [Abstract][Full Text] [Related]
2. Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer: A Secondary Analysis of 2 Randomized Clinical Trials.
King MT; Chen MH; Collette L; Neven A; Bolla M; D'Amico AV
JAMA Netw Open; 2021 May; 4(5):e2111092. PubMed ID: 33999161
[TBL] [Abstract][Full Text] [Related]
3. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials.
D'Amico AV; Chen MH; de Castro M; Loffredo M; Lamb DS; Steigler A; Kantoff PW; Denham JW
Lancet Oncol; 2012 Feb; 13(2):189-95. PubMed ID: 22112793
[TBL] [Abstract][Full Text] [Related]
4. Time to Prostate-specific Antigen Nadir and the Risk of Death From Prostate Cancer Following Radiation and Androgen Deprivation Therapy.
Pike LRG; Wu J; Chen MH; Loffredo M; Renshaw AA; Pfail J; Kantoff PW; D'Amico AV
Urology; 2019 Apr; 126():145-151. PubMed ID: 30664895
[TBL] [Abstract][Full Text] [Related]
5. The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer.
Patel SA; Chen MH; Loffredo M; Renshaw A; Kantoff PW; D'Amico AV
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):234-240. PubMed ID: 28117382
[TBL] [Abstract][Full Text] [Related]
6. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
D'Amico AV; Chen MH; Renshaw AA; Loffredo M; Kantoff PW
JAMA; 2008 Jan; 299(3):289-95. PubMed ID: 18212313
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality.
Bitterman DS; Chen MH; Wu J; Renshaw AA; Loffredo M; Kantoff PW; Small EJ; D'Amico AV
Cancer; 2021 Aug; 127(15):2623-2630. PubMed ID: 33823065
[TBL] [Abstract][Full Text] [Related]
8. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
Atkins KM; Chen MH; Wu J; Renshaw AA; Loffredo M; Kantoff PW; Small EJ; D'Amico AV
Cancer; 2018 Apr; 124(7):1383-1390. PubMed ID: 29266181
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
[TBL] [Abstract][Full Text] [Related]
10. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
11. Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality.
Mahal BA; Chen MH; Renshaw AA; Loffredo MJ; Kantoff PW; D'Amico AV
J Natl Compr Canc Netw; 2018 Jun; 16(6):727-734. PubMed ID: 29891524
[No Abstract] [Full Text] [Related]
12. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
[TBL] [Abstract][Full Text] [Related]
13. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
Choueiri TK; Xie W; D'Amico AV; Ross RW; Hu JC; Pomerantz M; Regan MM; Taplin ME; Kantoff PW; Sartor O; Oh WK
Cancer; 2009 Mar; 115(5):981-7. PubMed ID: 19152438
[TBL] [Abstract][Full Text] [Related]
14. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
D'Amico AV; Moul JW; Carroll PR; Cote K; Sun L; Lubeck D; Renshaw AA; Loffredo M; Chen MH
J Natl Cancer Inst; 2004 Apr; 96(7):509-15. PubMed ID: 15069112
[TBL] [Abstract][Full Text] [Related]
15. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
[TBL] [Abstract][Full Text] [Related]
16. Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials.
Nikitas J; Ong WL; Carrier N; Romero T; Millar J; Steinberg ML; Rettig MB; Boutros PC; Reiter R; Nickols NG; Valle L; McGuire SE; Spratt DE; Souhami L; Roy S; Martin JM; Joseph D; Nabid A; Kishan AU
Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):826-831. PubMed ID: 38151191
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence.
Wo JY; Chen MH; Nguyen PL; Renshaw AA; Loffredo MJ; Kantoff PW; D'Amico AV
J Clin Oncol; 2009 Dec; 27(35):6000-5. PubMed ID: 19858385
[TBL] [Abstract][Full Text] [Related]
18. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
D'Amico AV; Loffredo M; Renshaw AA; Loffredo B; Chen MH
J Clin Oncol; 2006 Sep; 24(25):4190-5. PubMed ID: 16943536
[TBL] [Abstract][Full Text] [Related]
19. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
20. Risk of Short-Term Prostate-Specific Antigen Recurrence and Failure in Patients With Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sayan M; Huang J; Xie W; Chen MH; Loffredo M; McMahon E; Orio P; Nguyen P; D'Amico AV
JAMA Netw Open; 2023 Oct; 6(10):e2336390. PubMed ID: 37801315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]